Ziv-aflibercept Efficacy in Better Regulating AMD

Part of paid clinical trials in Virginia Beach, Virginia.

Sponsor
Kapil Kapoor
Study ID
NCT03423823
Phase
PHASE2
Status
Completed

Conditions

  • Wet Age-related Macular Degeneration
  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a randomized, open-label, interventional, controlled study to determine the effects of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control anti-vascular endothelial growth factor ("anti-VEGF") injections (bevacizumab, ranibizumab, or aflibercept).

Key Dates

Start date
Jul 7, 2017
Status verified
Oct 2020
Primary completion
Jun 26, 2020
Completion
Jun 26, 2020

Study Design

Enrollment
62 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Study Drug Arm
    Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
  • Other: Control Arm
    Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)

Primary Outcome Measure

Efficacy of study drug measured by change in best corrected visual acuity [ Time Frame: 18 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Wagner Macula & Retina CenterVirginia BeachVirginia23454-

Find similar trials in Virginia Beach, VA

By research site
Wagner Macula & Retina Center· Virginia Beach, VA

Related Studies